Advanced search×

Stilbene derivatives that are colchicine-site microtubule inhibitors have antileukemic activity and minimal systemic toxicity.

Am J Hematol 83(5):390-7 (2008) PMID 18175355

Stilbenes are a group of natural compounds with many biological activities. Two highly potent stilbenes, cis-3,4',5-trimethoxy-3'-aminostilbene (stilbene 5c) and cis-3,4',5-trimethoxy-3'-hydroxystilbene (stilbene 6c) induce G2/M cell-cycle arrest and leukemic cell death in nanomolarity range without affecting normal bone marrow progenitor cells. The mechanism of stilbenes is mediated by interfering with microtubule polymerization through the colchicine-binding site. Docking of the stilbenes into tubulin structure confirms that stilbenes fit into the colchicine-binding pocket. Animal studies show that stilbenes are well tolerated in mice and are capable of inducing more than 50% leukemic cell death by a single dose injection. A 5-day treatment with low-dose stilbenes suppresses tumor growth in mice with established tumor xenografts. No major organ damage was detected by histological section. Our results indicate that stilbene 5c is a microtubule-interfering agent and can be potentially useful in leukemic therapy.

DOI: 10.1002/ajh.21104
Version: za2963e q8za9 q8zb5 q8zcf q8zd2 q8ze4 q8zf0 q8zg9

Similar articles you may find interesting…

  1. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MA...

    FASEB J 24(12):4722-32 (2010) PMID 20696856 PMCID PMC2992378

    We demonstrate that flavokawain B (FKB), a chalcone from kava root, is a potent hepatocellular toxin, inducing cell death in HepG2 (LD50=15.3+/-0.2 muM) and L-02 (LD50=32 muM) cells. Hepatocellular toxicity of FKB is mediated by induction of oxidative stress, depletion of reduced glutathione (GSH),...
  2. Analysis of the genome to personalize therapy for melanoma.

    Oncogene 29(41):5545-55 (2010) PMID 20697348 PMCID PMC3169242

    We will discuss the molecular targets that have been validated clinically, additional genetic events that are candidates for future trials, and the challenges that remain to improve outcomes further in this aggressive disease.Oncogene advance online publication, 9 August 2010; doi:10.1038/onc.2010.3...